WuXi Biologics is giving CDMO Terumo the keys to its site in Leverkusen, Germany, with a 150 million euros ($167 million) ...

WuXi Biologics ("WuXi Bio"), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), ...

WuXi Biologics is a leading global CRDMO ... to seamlessly advance our clients' molecules from concept to CMC development.

It also delivers a comprehensive and cost-effective chemistry, manufacturing and controls (CMC) strategy. As part of WuXi Biologics' integrated technology offerings, which are based on microbial ...

SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been ...

Contributing to United Nations Sustainable Development Goals Enhancing transparency and effectiveness for corporate governance Empowering employees and delivering positive impact to communities ...

WuXi Biologics' innovative process technologies have been instrumental in achieving remarkable PPQ outcomes: Protein production costs per gram were reduced by nearly 70%, while advanced mass ...

Unleashing the power of its unique CRDMO business model, technology strength and operational excellence, WuXi Biologics has successfully continued to execute its "Follow and Win the Molecule ...

HONG KONG, April 29, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the ...